ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study

Trial ID or NCT#

NCT02021279

Status

not recruiting iconNOT RECRUITING

Purpose

The primary objective of this study is to assess the safety and effectiveness of MatriStem Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ prolapse. Patients are evaluated throughout a 3 year follow-up period.

Official Title

Evaluation of the Use of Transvaginal Resorbable Biologic Mesh as Compared to Traditional Non-Mesh Surgical Repair for Treating Pelvic Floor Disorders

Eligibility Criteria

Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Eric R. Sokol, MD
Eric R. Sokol, MD
Urogynecologist, Pelvic surgeon, Minimally invasive gynecologic surgeon, Pelvic reconstructive surgeon, Obstetrician and Gynecologist (OB-GYN)
Professor of Obstetrics and Gynecology (Gynecology and Gynecologic Specialties/Urogynecology) and, by courtesy, of Urology

Contact us to find out if this trial is right for you.

Contact

Tine Bjornlund
650-724-7826

View on ClinicalTrials.gov